Rubedo Life Sciences

Developing Senolytic Pro-Drugs for Age Related Diseases


Rubedo Life Sciences is developing senolytic therapies for age related diseases. Underpinned by a bioinformatics and computational platform, the company identifies metabolic changes between senescent (stressed and damaged cells that accumulate with age) and healthy cells to design pro-drug strategies to reduce off target side effects.

Key People

Mark Gallop, PhD
Marco Quarta, PhD
Julian Klein


Genetics & Platform Technologies

prev page Pictura Bio next page Sunfire

We use cookies to give you the best experience on our website. Learn more.